Navigation Links
Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
Date:11/21/2007

First U.S. resolution to shine spotlight on crisis affecting 246 million

people worldwide

PRINCETON, N.J., Nov. 21 /PRNewswire-FirstCall/ -- On the eve of World Diabetes Day, leaders in the U.S. House of Representatives passed House Concurrent Resolution 211 supporting the goals and ideals of World Diabetes Day, which is recognized annually on November 14. Then, the next day, on World Diabetes Day itself, the U.S. Senate followed suit, passing Senate Resolution 382. More than 20 million Americans have diabetes, and that number is expected to double by 2025.

Passage of the U.S. resolution marks the first time Congress has officially supported World Diabetes Day since it was established in 1991 by the World Health Organization and the International Diabetes Federation, of which Novo Nordisk is a member. It represents an important milestone in a busy month of activities taking place as part of National Diabetes Month.

As the lead industry supporter of the resolution, Novo Nordisk and its National Changing Diabetes(R) Program have worked closely with many of the resolution sponsors, including Reps. Donald Payne (D-N.J.) and Donald Manzullo (R-Ill.) and Sens. Debbie Stabenow (D-Mich.), Pete Domenici (R-N.M.), Frank Lautenberg (D-N.J.) and Norman Coleman (R-Minn.) to help focus attention on diabetes and make the disease a top national health care priority.

"With over 80 years in diabetes care, Novo Nordisk commends the leadership and commitment of Representatives Payne and Manzullo and Senators Stabenow, Domenici, Lautenberg and Coleman, and the entire Congress. The attention and urgency these resolutions will bring to diabetes prevention and treatment efforts in the United States is a positive step forward in our shared passion of changing diabetes," said Martin Soeters, president of Novo Nordisk Inc.

The United Nations General Assembly passed a World Diabetes Day Resolution on December 20, 2006, recognizing diabetes as a chronic, debilitating and costly disease that is associated with major complications and poses severe risks for families, countries and the global community.

In addition to supporting diabetes awareness on a national level, Novo Nordisk is active at the state level, working closely with elected officials and diabetes leaders to introduce proclamations in support of World Diabetes Day in Florida, Georgia, Mississippi, New Jersey and West Virginia.

For more information on Novo Nordisk and the National Changing Diabetes(R) Program visit novonordisk-us.com and ncdp.com.

About Novo Nordisk

Novo Nordisk is a health care company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com. Further information:


'/>"/>
SOURCE Novo Nordisk
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
2. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
3. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
4. FRC Applauds New Ballot Initiative for Cures Without Cloning
5. YM Biosciences announces adoption of renewed Shareholders Rights Plan
6. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
7. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
8. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
9. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
10. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
11. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... For the months ... produced a Spotlight series on “Cell Therapy Regulation” for its regenerative ... experts on the unique regulatory challenges of stem cell medical research. , Stem ...
(Date:6/22/2017)... ... June 22, 2017 , ... RURO, Inc., ... Limfinity® version 6.5, a content-packed update to the Limfinity® framework. , LimitLIS® and ... and more diverse base of customers among labs and other businesses. Limfinity® 6.5 ...
(Date:6/20/2017)... ... ... Biologist Dawn Maslar MS has found a biomarker that she claims verifies ... The Neuroscience of Meeting, Dating, Losing Your Mind, and Finding True Love, Maslar found ... step, in my estimation, was to scientifically track the evidence of commitment in men,” ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... PhD, a well-versed leader with extensive assay development and biomarker expertise, as VP ... is a Boston CRO specializing in bio-analytical assay development and sample testing services. ...
Breaking Biology Technology:
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:3/22/2017)... NEW YORK , March 21, 2017 /PRNewswire/ ... Customer Marketing Cloud used by retailers such as ... in its platform — Product Recommendations and Replenishment. Using ... to give more personalized product and replenishment recommendations ... purchases, but also on predictions of customer intent ...
Breaking Biology News(10 mins):